Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| microglial cell | 10 studies | 38% ± 13% | |
| macrophage | 6 studies | 35% ± 18% | |
| adipocyte | 5 studies | 19% ± 2% | |
| mast cell | 3 studies | 22% ± 10% | |
| fibroblast | 3 studies | 50% ± 28% | |
| monocyte | 3 studies | 43% ± 30% | |
| endothelial cell | 3 studies | 31% ± 19% |
Insufficient scRNA-seq data for expression of PLA2G4A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 765.97 | 577 / 578 | 91% | 42.95 | 1050 / 1155 |
| esophagus | 99% | 578.27 | 1425 / 1445 | 89% | 25.44 | 163 / 183 |
| prostate | 100% | 913.08 | 245 / 245 | 85% | 10.00 | 429 / 502 |
| pancreas | 87% | 261.83 | 285 / 328 | 94% | 19.54 | 168 / 178 |
| skin | 97% | 753.13 | 1752 / 1809 | 83% | 25.22 | 394 / 472 |
| bladder | 100% | 2003.86 | 21 / 21 | 74% | 19.71 | 374 / 504 |
| uterus | 100% | 946.42 | 170 / 170 | 74% | 20.98 | 339 / 459 |
| ovary | 98% | 498.27 | 176 / 180 | 75% | 11.91 | 322 / 430 |
| intestine | 100% | 1208.97 | 965 / 966 | 64% | 16.16 | 338 / 527 |
| stomach | 90% | 568.07 | 322 / 359 | 67% | 16.76 | 193 / 286 |
| kidney | 97% | 702.02 | 86 / 89 | 58% | 5.93 | 521 / 901 |
| breast | 100% | 568.12 | 458 / 459 | 48% | 7.30 | 538 / 1118 |
| brain | 62% | 181.98 | 1651 / 2642 | 85% | 12.67 | 596 / 705 |
| thymus | 98% | 399.19 | 637 / 653 | 39% | 3.02 | 234 / 605 |
| adrenal gland | 100% | 1078.66 | 257 / 258 | 25% | 3.57 | 58 / 230 |
| ureter | 0% | 0 | 0 / 0 | 100% | 8.21 | 1 / 1 |
| adipose | 100% | 759.43 | 1202 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 540.58 | 1315 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 98% | 459.87 | 236 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 81% | 382.59 | 750 / 929 | 0% | 0 | 0 / 0 |
| heart | 75% | 387.25 | 648 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 73% | 13.05 | 33 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 38% | 2.78 | 11 / 29 |
| eye | 0% | 0 | 0 / 0 | 24% | 1.80 | 19 / 80 |
| liver | 10% | 18.22 | 23 / 226 | 5% | 0.65 | 22 / 406 |
| muscle | 7% | 11.49 | 54 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006640 | Biological process | monoacylglycerol biosynthetic process |
| GO_0071236 | Biological process | cellular response to antibiotic |
| GO_0036151 | Biological process | phosphatidylcholine acyl-chain remodeling |
| GO_0006663 | Biological process | platelet activating factor biosynthetic process |
| GO_0006690 | Biological process | icosanoid metabolic process |
| GO_0019370 | Biological process | leukotriene biosynthetic process |
| GO_0051649 | Biological process | establishment of localization in cell |
| GO_0043032 | Biological process | positive regulation of macrophage activation |
| GO_0034638 | Biological process | phosphatidylcholine catabolic process |
| GO_0001516 | Biological process | prostaglandin biosynthetic process |
| GO_0046475 | Biological process | glycerophospholipid catabolic process |
| GO_0006071 | Biological process | glycerol metabolic process |
| GO_0032308 | Biological process | positive regulation of prostaglandin secretion |
| GO_0002827 | Biological process | positive regulation of T-helper 1 type immune response |
| GO_0010572 | Biological process | positive regulation of platelet activation |
| GO_0050482 | Biological process | arachidonic acid secretion |
| GO_0019369 | Biological process | arachidonic acid metabolic process |
| GO_0034478 | Biological process | phosphatidylglycerol catabolic process |
| GO_0042127 | Biological process | regulation of cell population proliferation |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005635 | Cellular component | nuclear envelope |
| GO_0005743 | Cellular component | mitochondrial inner membrane |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005634 | Cellular component | nucleus |
| GO_0047498 | Molecular function | calcium-dependent phospholipase A2 activity |
| GO_0008374 | Molecular function | O-acyltransferase activity |
| GO_0005544 | Molecular function | calcium-dependent phospholipid binding |
| GO_0070273 | Molecular function | phosphatidylinositol-4-phosphate binding |
| GO_0004623 | Molecular function | phospholipase A2 activity |
| GO_0047499 | Molecular function | calcium-independent phospholipase A2 activity |
| GO_0032266 | Molecular function | phosphatidylinositol-3-phosphate binding |
| GO_1902387 | Molecular function | ceramide 1-phosphate binding |
| GO_0004622 | Molecular function | lysophospholipase activity |
| GO_0102545 | Molecular function | phosphatidyl phospholipase B activity |
| GO_0005509 | Molecular function | calcium ion binding |
| GO_0010314 | Molecular function | phosphatidylinositol-5-phosphate binding |
| Gene name | PLA2G4A |
| Protein name | Cytosolic phospholipase A2 alpha (EC 3.1.1.4) Cytosolic phospholipase A2 (Phospholipase A2, group IVA (Cytosolic, calcium-dependent), isoform CRA_a) Cytosolic phospholipase A2 (cPLA2) (Phospholipase A2 group IVA) [Includes: Phospholipase A2 (EC 3.1.1.4) (Phosphatidylcholine 2-acylhydrolase); Lysophospholipase (EC 3.1.1.5)] |
| Synonyms | CPLA2 PLA2G4 hCG_41183 |
| Description | FUNCTION: Has primarily calcium-dependent phospholipase and lysophospholipase activities, with a major role in membrane lipid remodeling and biosynthesis of lipid mediators of the inflammatory response . Plays an important role in embryo implantation and parturition through its ability to trigger prostanoid production (By similarity). Preferentially hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) . Selectively hydrolyzes sn-2 arachidonoyl group from membrane phospholipids, providing the precursor for eicosanoid biosynthesis via the cyclooxygenase pathway . In an alternative pathway of eicosanoid biosynthesis, hydrolyzes sn-2 fatty acyl chain of eicosanoid lysophopholipids to release free bioactive eicosanoids . Hydrolyzes the ester bond of the fatty acyl group attached at sn-1 position of phospholipids (phospholipase A1 activity) only if an ether linkage rather than an ester linkage is present at the sn-2 position. This hydrolysis is not stereospecific . Has calcium-independent phospholipase A2 and lysophospholipase activities in the presence of phosphoinositides . Has O-acyltransferase activity. Catalyzes the transfer of fatty acyl chains from phospholipids to a primary hydroxyl group of glycerol (sn-1 or sn-3), potentially contributing to monoacylglycerol synthesis . . |
| Accessions | W0FXB0 Q14064 P47712 ENST00000367466.4 |
